Dr. David A. Sinclair is a professor of genetics at Harvard Medical School and one of the most visible scientists in longevity research. His work has helped push aging biology into the public conversation, especially the ideas that cells lose important regulatory information over time and that some age-related changes may be reversible.
October 22, 2026 update: ER-100 reaches humans
On October 8, Life Biosciences reported interim results from the first three participants treated in its Phase 1 trial of ER-100. All three had open-angle glaucoma and received the trial’s lowest dose: a single injection into the eye, followed by daily oral doxycycline for 56 days to switch on controlled expression of three reprogramming factors—OCT4, SOX2 and KLF4, collectively called OSK. A steroid taper was used to reduce inflammation risk from the viral vector.
According to the company, treatment was well tolerated through day 56, with no dose-limiting toxicities, serious adverse events or adverse events of special interest reported. The trial’s safety-monitoring board recommended moving to the next dose. The company also reported improved visual-field measurements in two of the three participants.
That is encouraging enough to justify continued study. It is not yet proof that ER-100 restores vision, rejuvenates human cells or reverses aging. These are company-reported interim observations from three people in an open-label, uncontrolled safety trial. The results have not been published as a complete peer-reviewed clinical paper; follow-up is short; and visual-field testing can vary with attention, fatigue and familiarity with the test. A larger controlled study would be needed to separate a treatment effect from normal variation, practice effects or chance.
Why this trial is connected to Sinclair
ER-100 grew out of research by Sinclair and collaborators showing that controlled OSK expression could restore some visual function in mouse models of glaucoma. Sinclair co-founded Life Biosciences, has disclosed equity and board involvement, and is an inventor on intellectual property licensed to the company. Several researchers involved in the preclinical work also disclosed company employment, equity or funding.
Those relationships do not negate the research, but they make independent replication and complete clinical reporting especially important. The October 8 interim results were released by Life Biosciences, the therapy’s developer—not by an independent research group.
ER-100 is an investigational gene therapy delivered by an adeno-associated viral vector. It is not a supplement, is not approved for routine care and should not be confused with do-it-yourself “rejuvenation” protocols. Its progress does not validate NMN, resveratrol or commercial biological-age tests.
October 2026 update: interventions and epigenetic clocks
A 2026 peer-reviewed review coauthored by Sinclair examined 41 human studies in which an intervention changed—or failed to change—at least one newer epigenetic aging clock. The authors reported clock decreases in studies of interventions ranging from exercise and plant-rich diets to semaglutide, calorie restriction, omega-3 fatty acids and several pharmaceuticals. In the studies they reviewed, nicotinamide riboside, rapamycin and senolytics did not show a detectable clock effect.
This does not establish that the interventions with lower clock scores extend life, and it does not prove that interventions without a clock effect are ineffective for their approved medical uses. The studies used different populations, durations, interventions and clock algorithms. A methylation-clock change is an investigational biomarker—not direct evidence of fewer heart attacks, less dementia, greater physical function or longer survival.
The review is useful because it organizes a fast-growing human evidence base and reinforces an important lesson: biological-age tests can generate hypotheses, but they cannot yet serve as a universal scorecard for whether a longevity treatment works.
What Sinclair’s lab is working on
1. Epigenetic information and aging
Your DNA sequence is only part of the biological story. Cells also use an epigenetic control system—chemical marks and structural cues that help determine which genes are active. Sinclair’s “information theory of aging” proposes that cellular stress and DNA repair gradually disrupt this control system, causing cells to lose aspects of their identity and function.
In a 2023 Cell study, researchers created controlled DNA breaks in mice without changing the DNA sequence. The mice developed molecular and physical signs associated with aging. Activating OSK reversed some of those changes. This supports the hypothesis in that experimental model; it does not establish that epigenetic information loss is the sole cause of human aging.
2. Partial cellular reprogramming
Full reprogramming can return a mature cell to a stem-cell-like state, which would erase the cell’s useful identity and can create serious safety problems. Partial reprogramming aims to restore more youthful gene regulation without pushing the cell that far backward.
In a 2020 Nature paper, Sinclair and collaborators delivered OSK genes to retinal ganglion cells in mice. The intervention restored younger DNA-methylation patterns, promoted nerve regeneration after injury and improved vision in mouse models of glaucoma and age-related vision loss. A later mouse study reported sustained visual improvements with controlled OSK expression. ER-100 now translates that targeted approach into early human safety testing, but clinical benefit remains unproven.
3. NAD, sirtuins and cellular stress defenses
Sinclair’s earlier work centered on sirtuins, enzymes involved in metabolism, DNA repair and cellular stress responses. Sirtuins depend on nicotinamide adenine dinucleotide, or NAD, a molecule involved in energy metabolism. His lab continues to study compounds that influence sirtuins and ways to raise cellular NAD levels.
A small 90-day randomized trial coauthored by Sinclair tested an experimental NAD precursor, MIB-626, in overweight or obese middle-aged and older adults. It increased circulating NAD and changed several secondary measures. The study was not evidence that NMN slows aging, prevents disease or extends human life. Results for one proprietary compound also should not be generalized to every over-the-counter “NAD booster.”
4. Mitochondria and the aging brain
The lab also studies why communication between the nucleus and mitochondria deteriorates with age, how mitochondrial NAD may affect cell survival and which genes regulate mitochondrial function. Current projects apply genetic models and molecular profiling to age-related neurodegeneration and memory loss.
What has—and has not—been demonstrated
| Claim | Evidence today |
|---|---|
| Epigenetic disruption can drive aging-like changes | Supported in a controlled mouse model; its role and relative importance in human aging remain under study. |
| Partial reprogramming can restore function | Promising mouse eye and nerve results; a three-person Phase 1 company update provides early tolerability observations. Human efficacy, durability, dosing and long-term safety are not established. |
| ER-100 reverses human aging | No. It is being tested for specific optic-nerve diseases. The first update was short, uncontrolled and designed primarily to assess safety. |
| Raising NAD improves human longevity | Some short trials show that compounds can raise NAD and affect biomarkers. No trial has shown a longer human lifespan. |
| Resveratrol is a proven anti-aging treatment | No. Mechanistic and preclinical interest has not translated into proof that it extends healthy human life. |
| A biological-age test tells you how long you will live | No. Epigenetic clocks can be useful research tools, but a changing score is not the same as proven disease prevention or added years of life. |
Why the excitement needs guardrails
Reprogramming affects the machinery that controls cell identity. The same power that makes it scientifically exciting also creates concerns about unwanted cell growth, loss of identity, immune effects and delivering the right dose to the right tissue. Short-term tolerability in three eyes cannot resolve those long-term questions.
There is also a commercial layer. The Sinclair Lab’s disclosure page lists Sinclair as a founder, investor, equity holder, advisor, board member and inventor on licensed intellectual property connected with Life Biosciences. The preclinical OSK paper likewise discloses equity, patents, company employment and company funding. Readers should look for future peer-reviewed clinical reports, prespecified outcomes, longer follow-up and independent confirmation.
What this means for you after 50
Follow the research, but do not treat early-stage biology as a personal protocol. There is currently no Sinclair-inspired stack proven to extend human life. NMN and resveratrol can add cost, uncertainty and possible interactions without solving the health risks most likely to shorten your healthy years.
The highest-confidence longevity work remains less futuristic: preserve muscle and power, build aerobic fitness, manage blood pressure and cholesterol, avoid tobacco, sleep consistently, maintain vaccination and screening, and work with a clinician on individual risks. Those actions may sound ordinary. Their evidence is anything but.
Frequently asked questions
Does ER-100 prove that age reversal works in humans?
No. It provides an initial short-term safety observation in three people with glaucoma. It does not prove cellular rejuvenation, restored vision, whole-body age reversal or longer life.
Is David Sinclair a medical doctor?
No. He holds a Ph.D. and is a professor of genetics, not a physician. “Dr.” refers to his doctoral degree.
Should I take NMN or resveratrol?
Neither is proven to extend human lifespan. Discuss any supplement with a qualified clinician, especially if you take medication, have a medical condition or are preparing for surgery.
Primary and institutional sources
- ClinicalTrials.gov: Phase 1 ER-100 study, NCT07290244
- Life Biosciences: company-reported interim ER-100 results, October 8, 2026
- Lu et al., Nature (2020): Reprogramming to recover youthful epigenetic information and restore vision
- Karg et al. (2023): Sustained vision recovery by OSK gene therapy in a mouse glaucoma model
- Yang et al., Cell (2023): Loss of epigenetic information as a cause of mammalian aging
- Pencina et al. (2023): NAD augmentation in middle-aged and older adults
- Johnson and Sinclair (2026): Interventions that affect next-generation epigenetic aging clocks
- Sinclair Lab: disclosed affiliations and commercial interests
Reviewed and updated October 22, 2026. This article is educational and does not provide medical advice.